Dilip Shanghvi’s son Aalok to head emerging mkts unit after Sun Pharma buys Ranbaxy

By PTI
13 March, 2015

Taking forward its acquisition of Ranbaxy Laboratories, Sun Pharma has put in place a team of top executives, including Dilip Shanghvi’s son Aalok Shanghvi, to lead the businesses of both the organisations.

While the leadership team is comprised mainly from the representatives of Sun Pharma, it also has executives from Ranbaxy, drawing upon expertise, experience and contribution of the chosen leaders from both the organisations.

Aalok would head emerging market businesses, currently under folds of Sun and Ranbaxy, while Sun’s India business head Abhay Gandhi will take charge of domestic business of both the companies, sources said.

Kal Sundaram, who is CEO of North America business for Sun Pharma will lead the North American business for both the organisations. He will also continue to be CEO of Taro.

The group is looking into a new role for Ranbaxy CEO and MD Arun Sawhney.

“The leadership team for Sun Pharma as a combined entity has been announced internally. This leadership team comprising members of Sun Pharma and Ranbaxy draws upon the strategic expertise, collective industry experience and proven track record of chosen leaders within both the organisations,” Sun Pharma’s official spokesperson said in an e-mailed response.

They have been selected based on their contribution and performance since last couple of years after several rounds of discussions supplemented with feedback from a talent mapping process undertaken by a global firm, he added.

The new team becomes effective from the date of merger, the spokesperson said.

On the role that the current CEO and MD of Ranbaxy Arun Sawhney will have, he said: “An appropriate role is currently being evaluated for Arun.” 

Similarly, “there are many other senior leaders in both organisations who will be contributing to our success in the future and we will need all their support and involvement in driving the future goals of the combined entity. Currently, we are exploring ways to involve them to contribute to the combined entity,” the spokesperson said.

Sun Pharmaceutical Industries has received most approvals for the USD 4-billion merger deal.

However, Competition Commission of India (CCI) has given a conditional approval to the deal and has asked the two companies to divest some key products to address the anti-competitive issues.


Leave Your Comment
Sun Pharma to buy Ranbaxy in $3.2B all-stock deal

Sun Pharma to buy Ranbaxy in $3.2B all-stock deal

TEAM VCC 3 years ago
Sun Pharmaceutical Industries Ltd, the country’s top drugmaker by market cap, is acquiring Ranbaxy Laboratories Ltd in an all-stock transaction, creating the world’s fifth-largest generics...
Sun Pharma to acquire majority stake in Russia’s Biosintez

Sun Pharma to acquire majority stake in Russia’s Biosintez

Joseph Rai 9 months ago
Sun Pharmaceutical Industries Ltd said on Wednesday it has agreed to acquire an 85.1% stake in Russian drugmaker JSC Biosintez as part of its strategy...
Sun Pharma-Ranbaxy begin integration after completing merger formalities

Sun Pharma-Ranbaxy begin integration after completing merger formalities

Jasleen Kaur Batra 2 years ago
Sun Pharmaceutical Industries Ltd on Wednesday said it has started the integration process to complete its buyout of Ranbaxy Laboratories Ltd thereby creating India’s largest...
No Comments

Dilip Shanghvi’s son Aalok to head emerging mkts unit after Sun Pharma buys Ranbaxy

Powered by WordPress.com VIP